1. Home
  2. EVAX vs MBIO Comparison

EVAX vs MBIO Comparison

Compare EVAX & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVAX
  • MBIO
  • Stock Information
  • Founded
  • EVAX 2008
  • MBIO 2015
  • Country
  • EVAX Denmark
  • MBIO United States
  • Employees
  • EVAX N/A
  • MBIO N/A
  • Industry
  • EVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • MBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVAX Health Care
  • MBIO Health Care
  • Exchange
  • EVAX Nasdaq
  • MBIO Nasdaq
  • Market Cap
  • EVAX 10.8M
  • MBIO 4.7M
  • IPO Year
  • EVAX 2021
  • MBIO N/A
  • Fundamental
  • Price
  • EVAX $2.30
  • MBIO $3.34
  • Analyst Decision
  • EVAX Strong Buy
  • MBIO
  • Analyst Count
  • EVAX 2
  • MBIO 0
  • Target Price
  • EVAX $10.00
  • MBIO N/A
  • AVG Volume (30 Days)
  • EVAX 113.7K
  • MBIO 15.5M
  • Earning Date
  • EVAX 08-13-2025
  • MBIO 08-12-2025
  • Dividend Yield
  • EVAX N/A
  • MBIO N/A
  • EPS Growth
  • EVAX N/A
  • MBIO N/A
  • EPS
  • EVAX N/A
  • MBIO N/A
  • Revenue
  • EVAX $3,293,000.00
  • MBIO N/A
  • Revenue This Year
  • EVAX N/A
  • MBIO N/A
  • Revenue Next Year
  • EVAX N/A
  • MBIO N/A
  • P/E Ratio
  • EVAX N/A
  • MBIO N/A
  • Revenue Growth
  • EVAX 2555.64
  • MBIO N/A
  • 52 Week Low
  • EVAX $1.20
  • MBIO $0.89
  • 52 Week High
  • EVAX $17.75
  • MBIO $25.00
  • Technical
  • Relative Strength Index (RSI)
  • EVAX 46.42
  • MBIO 75.63
  • Support Level
  • EVAX $2.35
  • MBIO $1.17
  • Resistance Level
  • EVAX $2.60
  • MBIO $2.13
  • Average True Range (ATR)
  • EVAX 0.26
  • MBIO 0.43
  • MACD
  • EVAX -0.05
  • MBIO 0.16
  • Stochastic Oscillator
  • EVAX 26.14
  • MBIO 40.07

About EVAX Evaxion Biotech

Evaxion AS is in the field of oncology. It used the AI-Immunology platform.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: